Israel Englander Anavex Life Sciences Corp. Transaction History

Millennium Management LLC

$207 Billion
Q2 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Millennium Management LLC holds 37,814 shares of AVXL stock, worth $294,571. This represents 0.0% of its overall portfolio holdings.

Number of Shares

37,814

Previous 21,235 78.07%

Holding current value

$294,571

Previous $108,000 47.22%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$3.39 - $5.02 $56,202 - $83,226	16,579 Added 78.07%	37,814 $159,000
Q1 2024 May 15, 2024	SELL	$4.55 - $6.75 $22,827 - $33,864	-5,017 Reduced 19.11%	21,235 $108,000
Q4 2023 Feb 14, 2024	SELL	$5.04 - $9.95 $1.12 Million - $2.21 Million	-222,045 Reduced 89.43%	26,252 $244,000
Q2 2023 Aug 14, 2023	BUY	$7.66 - $9.5 $1.3 Million - $1.61 Million	169,649 Added 215.71%	248,297 $2.02 Million
Q1 2023 May 15, 2023	SELL	$8.32 - $11.75 $6.28 Million - $8.87 Million	-754,876 Reduced 90.56%	78,648 $674,000
Q4 2022 Feb 14, 2023	BUY	$7.65 - $14.43 $4.82 Million - $9.09 Million	630,156 Added 309.86%	833,524 $7.72 Million
Q3 2022 Nov 14, 2022	SELL	$8.9 - $12.86 $515,523 - $744,902	-57,924 Reduced 22.17%	203,368 $2.1 Million
Q2 2022 Aug 15, 2022	BUY	$7.31 - $12.84 $1.91 Million - $3.35 Million	261,292 New	261,292 $2.62 Million
Q1 2022 May 16, 2022	SELL	$9.74 - $17.69 $337,276 - $612,569	-34,628 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$16.88 - $23.31 $1.57 Million - $2.16 Million	-92,731 Reduced 72.81%	34,628 $600,000
Q3 2021 Nov 15, 2021	BUY	$16.82 - $25.75 $477,536 - $731,068	28,391 Added 28.69%	127,359 $2.29 Million
Q2 2021 Aug 16, 2021	BUY	$10.16 - $28.86 $1.01 Million - $2.86 Million	98,968 New	98,968 $2.26 Million
Q3 2020 Nov 16, 2020	SELL	$3.8 - $5.0 $39,364 - $51,795	-10,359 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$2.62 - $5.2 $260,121 - $516,271	-99,283 Reduced 90.55%	10,359 $51,000
Q1 2020 May 14, 2020	BUY	$2.38 - $5.81 $210,982 - $515,044	88,648 Added 422.25%	109,642 $345,000
Q4 2019 Feb 14, 2020	BUY	$2.31 - $3.14 $48,496 - $65,921	20,994 New	20,994 $54,000
Q3 2019 Nov 14, 2019	SELL	$2.22 - $3.9 $162,597 - $285,643	-73,242 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$2.75 - $3.7 $65,037 - $87,505	23,650 Added 47.69%	73,242 $247,000
Q1 2019 May 14, 2019	SELL	$1.68 - $3.42 $85,995 - $175,062	-51,188 Reduced 50.79%	49,592 $151,000
Q4 2018 Feb 14, 2019	SELL	$1.25 - $2.75 $585,726 - $1.29 Million	-468,581 Reduced 82.3%	100,780 $157,000
Q3 2018 Nov 14, 2018	SELL	$2.23 - $3.82 $219,309 - $375,677	-98,345 Reduced 14.73%	569,361 $1.55 Million
Q2 2018 Aug 14, 2018	BUY	$2.08 - $4.26 $1.39 Million - $2.84 Million	667,706 New	667,706 $1.75 Million
Q1 2018 May 15, 2018	SELL	$2.32 - $3.44 $104,156 - $154,438	-44,895 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$3.12 - $4.94 $68,312 - $108,161	21,895 Added 95.2%	44,895 $145,000
Q3 2017 Nov 14, 2017	BUY	$3.42 - $4.87 $78,660 - $112,010	23,000	23,000 $95,000

Others Institutions Holding AVXL

# of Institutions

155

Shares Held

26.5M

Call Options Held

673K

Put Options Held

811K

View Full List

About ANAVEX LIFE SCIENCES CORP.

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $607M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

More about AVXL

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account